Sarepta Therapeutics is selling off Arrowhead Pharmaceuticals’ shares to stretch its cash runway, while also inking a share ...

We recently published 10 Double-Digit Winners You Wish You Bought Yesterday. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is one of the last week’s top performers. Arrowhead Pharmaceuticals soared by ...

Shares of Sarepta Therapeutics hit their highest level in nearly a month on Wednesday after the company said a safety review ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...

The milestone payment is partially funded through Sarepta’s Arrowhead stock sale as both companies push forward with ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 third quarter ended June 30, 2025. The Company is hosting a conference call today, August 7, 2025, ...

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a biopharmaceutical company specializing in the development of RNAi therapeutics, with a diverse pipeline and strong partnerships within the industry.

Arrowhead Pharmaceuticals, Inc. Vince Anzalone, CFA 626-304-3400 [email protected] Investors: LifeSci Advisors, LLC Brian Ritchie 212-915-2578 [email protected] ...

An Arrowhead Pharmaceuticals “gene-silencing” drug that the biotech has been quietly researching as a gout treatment will continue its development under a partnership with Horizon Therapeutics.

What happened Shares of clinical-stage biotech company Arrowhead Pharmaceuticals (NASDAQ: ARWR) were up more than 17% Tuesday morning after the company released interim results from a phase 1/2 trial.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a small-cap biopharma that is developing a line therapies utilizing RNA interference (RNAI) to silence disease-causing genes. While the company has yet ...

Arrowhead Pharmaceuticals' development pipeline is chock-full of experimental new RNAi drugs including an antiviral treatment for chronic hepatitis B virus (HBV) that could become the new standard ...